Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

PURPOSE: When during cancer treatment resistance to a tyrosine kinase inhibitor (TKI) occurs, switching to another TKI is often considered as a reasonable option. Previously, we reported that resistance to sunitinib may be caused by increased lysosomal sequestration, leading to increased intracellul...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cell Oncol (Dordr)
Main Authors: Gotink, Kristy J., Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Dekker, Henk, Poel, Dennis, Azijli, Kaamar, Peters, Godefridus J., Broxterman, Henk J., Verheul, Henk M. W.
Formato: Artigo
Idioma:Inglês
Publicado: Springer Netherlands 2015
Assuntos:
Original Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4555235/
https://ncbi.nlm.nih.gov/pubmed/25665527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13402-015-0218-8
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares